Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.62 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.59 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27309803 | 1.00 | CRBN (1.00) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL34466336 | 1.00 | CRBN (1.00) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL29614679 | 1.00 | CRBN (1.00) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL29439976 | 0.90 | CRBN (1.00) | CRBN | |
| SCHEMBL21760366 | 0.90 | CRBN (1.00) | CRBN | |
| SCHEMBL21464551 | 0.89 | CRBN (0.80) | CRBNCSNK1A1IKZF2GSPT1DDB1 | |
| SCHEMBL25087702 | 0.88 | CRBN (0.78) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL20765391 | 0.86 | CRBN (0.75) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL29482963 | 0.86 | CRBN (0.75) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL31357772 | 0.85 | CRBN (0.74) | CRBNCSNK1A1IKZF2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4618755-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12377152-B2 | Compounds for degrading alpha-synuclein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (CN) | 2025-08-05 | — | — | US | disclosed |
| WO-2025108411-A1 | EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京沐华生物科技有限责任公司 | 2025-05-30 | — | — | WO | disclosed |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025076284-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-4504716-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | Cullgen (Shanghai), Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| CN-112261970-B | 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family zinc finger 2 (IKZF 2) dependent diseases | 诺华股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-112261970-B | 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family zinc finger 2 (IKZF 2) dependent diseases | 诺华股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2020227325-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-11-12 | — | — | WO | disclosed |
| US-10800770-B1 | Chroman derivatives having estrogen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-10-13 | — | — | US | disclosed |
| WO-2020200291-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020168172-A1 | CONJUGATE COMPOUNDS FOR THE DEGRADATION OF RAF | ZAMBONI CHEM SOLUTIONS INC. (CA) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020038415-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020012334-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020012334-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020012334-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | CRBN 4/4885CSNK1A1 73/4885IKZF2 899/4885 |
| US-10800770-B1 | Chroman derivatives having estrogen receptor degradation activity and uses thereof | ESR1, ESR2, ESRRG | CRBN 280/4885CSNK1A1 111/4885IKZF2 3330/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885CSNK1A1 322/4885IKZF2 3840/4885 |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | CRBN 5/4885CSNK1A1 1616/4885IKZF2 25/4885 |
| US-12377152-B2 | Compounds for degrading alpha-synuclein aggregates and uses thereof | SNCA, PARK7, PRNP | CRBN 610/4885CSNK1A1 2451/4885IKZF2 4361/4885 |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | ADRM1, BRDT, RBX1 | CRBN 82/4885CSNK1A1 1629/4885IKZF2 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.